Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ORPH

Orphazyme A/S (ORPH) Stock Price, News & Analysis

Orphazyme A/S logo

About Orphazyme A/S Stock (NASDAQ:ORPH)

Key Stats

Today's Range
N/A
50-Day Range
$0.57
$2.21
52-Week Range
N/A
Volume
941,400 shs
Average Volume
1.37 million shs
Market Capitalization
$30.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Receive ORPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orphazyme A/S and its competitors with MarketBeat's FREE daily newsletter.

ORPH Stock News Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
See More Headlines

ORPH Stock Analysis - Frequently Asked Questions

Orphazyme A/S (ORPH) raised $100 million in an initial public offering (IPO) on Tuesday, September 29th 2020. The company issued 7,600,000 shares at a price of $13.13 per share. BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Danske Markets was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orphazyme A/S investors own include AMC Entertainment (AMC), Digital World Acquisition (DWAC), NIO (NIO), Biora Therapeutics (BIOR), SNDL (SNDL), Tesla (TSLA) and Brigham Minerals (MNRL).

Company Calendar

Today
12/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORPH
Fax
N/A
Employees
141
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.74 per share

Miscellaneous

Free Float
N/A
Market Cap
$30.72 million
Optionable
Not Optionable
Beta
1.68
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ORPH) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners